1-(1-(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methyl)piperidin-4-yl)-3-(3-fluoro-5-(trifluoromethyl)phenyl)urea

ID: ALA396545

Chembl Id: CHEMBL396545

PubChem CID: 44427014

Max Phase: Preclinical

Molecular Formula: C23H29F4N3O

Molecular Weight: 439.50

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC1(C)[C@H]2CC=C(CN3CCC(NC(=O)Nc4cc(F)cc(C(F)(F)F)c4)CC3)[C@@H]1C2

Standard InChI:  InChI=1S/C23H29F4N3O/c1-22(2)15-4-3-14(20(22)11-15)13-30-7-5-18(6-8-30)28-21(31)29-19-10-16(23(25,26)27)9-17(24)12-19/h3,9-10,12,15,18,20H,4-8,11,13H2,1-2H3,(H2,28,29,31)/t15-,20-/m0/s1

Standard InChI Key:  UUKPEFZKFTUGFE-YWZLYKJASA-N

Associated Targets(Human)

CXCR3 Tchem C-X-C chemokine receptor type 3 (2736 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cxcr3 C-X-C chemokine receptor type 3 (96 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 439.50Molecular Weight (Monoisotopic): 439.2247AlogP: 5.42#Rotatable Bonds: 4
Polar Surface Area: 44.37Molecular Species: BASEHBA: 2HBD: 2
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.80CX Basic pKa: 9.00CX LogP: 4.19CX LogD: 2.58
Aromatic Rings: 1Heavy Atoms: 31QED Weighted: 0.49Np Likeness Score: -0.89

References

1. Allen DR, Bolt A, Chapman GA, Knight RL, Meissner JW, Owen DA, Watson RJ..  (2007)  Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.,  17  (3): [PMID:17097877] [10.1016/j.bmcl.2006.10.088]
2. Watson RJ, Allen DR, Birch HL, Chapman GA, Hannah DR, Knight RL, Meissner JW, Owen DA, Thomas EJ..  (2007)  Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.,  17  (24): [PMID:17964154] [10.1016/j.bmcl.2007.10.029]
3. Andrews SP, Cox RJ..  (2016)  Small Molecule CXCR3 Antagonists.,  59  (7): [PMID:26535614] [10.1021/acs.jmedchem.5b01337]

Source